Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quetiapine - AstraZeneca

Drug Profile

Quetiapine - AstraZeneca

Alternative Names: FK 949; FK949E; ICI 204636; Quetiapine extended release; Quetiapine fumarate; Quetiapine prolonged release; Seroquel; Seroquel XL; Seroquel XR

Latest Information Update: 06 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Astellas Pharma; AstraZeneca; Hutchison MediPharma; Luye Pharma Group
  • Class Analgesics; Antidepressants; Antipsychotics; Behavioural disorder therapies; Dibenzothiazepines; Mood stabilisers; Piperazines; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Alpha 2 adrenergic receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar depression; Bipolar disorders; Major depressive disorder; Manic episodes; Schizophrenia
  • Phase III Borderline personality disorders
  • Preregistration Submission Withdrawal Generalised anxiety disorder
  • No development reported Delirium; Irritable bowel syndrome
  • Discontinued Alcoholism; Behavioural disorders; Psychotic disorders

Most Recent Events

  • 30 Oct 2019 Quetiapine licensed to Cheplapharm Arzneimittel in Russia and Europe
  • 27 Mar 2019 Otsuka Pharmaceutical Development & Commercialization initiates enrolment in a phase I pharmacokinetic trial for Bipolar disorders and Schizophrenia in USA (PO) (NCT03872596)
  • 22 Jul 2018 Launched for Bipolar depression in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top